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Gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV), establish latency in B
cells. We hypothesized that the KSHV latency-associated nuclear antigen (LANA/orf73) provides a selective
advantage to infected B cells by driving proliferation in response to antigen. To test this, we used LANA B-cell
transgenic mice. Eight days after immunization with antigen without adjuvant, LANA mice had significantly
more activated germinal center (GC) B cells (CD19 PNA CD71) than controls. This was dependent upon
B-cell receptor since LANA did not restore the GC defect of CD19 knockout mice. However, LANA was able to
restore the marginal zone defect in CD19 knockout mice.
B-cell receptor (BCR) signaling is modulated at multiple
levels. CD19 impinges on antigen-dependent B-cell survival,
proliferation, and differentiation through direct interaction
with the BCR molecule (24, 51). Phosphatase and tensin ho-
molog deleted on chromosome 10 (PTEN) and Burton’s ty-
rosine kinase (BTK), as well as others, modulate cytoplasmic
second messenger and subsequent adaptor-dependent BCR
signaling steps (34). In fact, loss of PTEN can compensate for
the loss of CD19 function (6). We find that a viral protein of a
B-cell tropic human herpesvirus similarly modulates BCR sig-
naling in vivo, resulting in hyperactive naive B cells. This viral
protein is nuclear localized, and thus far most of its function-
ality has been attributed to transcriptional regulation and se-
quence-specific DNA binding. This protein is not an oncogene
as defined by the classic, cell autonomous transformation as-
say. Our in vivo data show that it is a subtler regulator of B-cell
differentiation and suggest a novel mechanism as to how im-
munotropic viruses modulate BCR signaling to further the
preferential survival and expansion of virally infected host cells
in vivo.
Kaposi sarcoma-associated herpesvirus (KSHV) is a B-cell
tropic human tumor virus. In addition to causing Kaposi sar-
coma, it is also the causative agent of a type of post-germinal
center (GC) diffuse large B-cell lymphoma (DLBCL), and
primary effusion lymphoma (PEL), as well as the plasmablastic
variant of multicentric Castleman’s disease (MCD) (9, 10).
KSHV can be found in peripheral blood, mature, CD19 B
cells (15, 37). During asymptomatic, latent persistence in
CD19 B cells, as well as in 99% of PEL cells in culture, only
the latency-associated nuclear antigen (LANA) and a few
other viral latent genes in the LANA latency locus are ex-
pressed (18, 20, 27, 45).
We previously generated transgenic mice, which express
LANA in CD19 mature B cells (21). In these mice LANA is
under the control of its own viral promoter, which is B cell
specific (28). LANA transgenic mice exhibit an activated ma-
ture B-cell phenotype, as evidenced by the expansion of
CD19 IgM IgD FSChi splenic B cells.
Functionally, B cells can be divided into follicular B cells (FL
cells), which respond to T-cell-dependent antigens, and mar-
ginal zone B cells (MZ cells), which respond to multivalent,
so-called T-cell-independent antigens. MZ cells also drive the
primary (days 2 to 4) low-affinity B-cell response to antigen
(reviewed in reference 26). Both populations require BCR
engagement and CD19 for proliferation and differentiation.
FL cells require T-cell help in their response to monovalent
antigens, e.g., the hapten 4-hydroxy-3-nitrophenylacetyl (NP).
The B-cell–T-cell interaction takes place in the germinal cen-
ters (GC). Note that there are three steps in follicular B-cell
activation: (i) antigen binding and transformation to activated
B-cell blasts, which are FSChi and express the CD71 and CD68
activation markers (31); (ii) T-cell-dependent activation and
migration into the GC; and (iii) T-cell-dependent class switch-
ing, GC exit, and differentiation (reviewed in reference 1).
MZ B cells do not necessarily require T-cell help, although
they do respond to T-cell-dependent antigens and are respon-
sible for the primary IgM response (54). In addition, strong,
multivalent antigens are thought to multimerize BCR mole-
cules to such an extent that MZ cell activation is induced
independently of direct T-cell contact (16, 35).
To test whether the LANA-induced hyperplasia is depen-
dent on BCR-transmitted activation signals, we crossed LANA
transgenic mice to isogenic CD19/ mice (19, 24, 51). We
found that the LANA transgene could not rescue the GC
B-cell deficiency of CD19/ mice. However, LANA was able
to rescue the MZ defect in CD19/ mice. We further found
that LANA augmented the primary B-cell response to acute
antigen, a finding consistent with a model in which LANA
lowers the threshold for BCR-dependent B-cell activation,
proliferation, and survival.
In the widest sense, these in vivo observations suggest that
antigen exposure fosters latent persistence of B-cell-tropic her-
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pesviruses, analogous to the way in which microbial translo-
cations foster T-cell activation and HIV replication (8).
Previously, it was reported that transgenic expression of the
Epstein-Barr virus (EBV) LMP1 protein accelerated ex-
trafollicular B-cell differentiation in vivo mimicking CD40
signaling (60), that EBV LMP2A enhances B-cell responses
(4, 56), and that murine herpesvirus 68 (MHV68) coinfec-
tion fosters macrophage responses to bacterial antigens (7).
The present study is the first demonstration that B cells
expressing a KSHV viral protein displayed enhanced re-
sponse to a T-dependent antigen.
MATERIALS AND METHODS
Mice. Transgenic mice expressing KSHV LANA were previously described
(21). CD19 knockout mice [C.129P2-Cd19tm1(cre)Cgn/J] were purchased from the
Jackson Laboratory (Bar Harbor, ME). LANA/ CD19 knockout mice were
obtained by breeding LANA transgenic mice with CD19 knockout mice. Mice
were maintained under pathogen-free conditions using ventilated cages. Animals
were injected intraperitoneally with 100 g of 4-hydroxy-3-nitrophenylacetyl–
keyhole limpet hemocyanin (NP-KLH; Biosearch Technologies, Inc., Novato,
CA) in 200 l of phosphate-buffered saline (PBS). All experiments were ap-
proved by the Institutional Animal Care and Use Committee (IACUC) at the
University of North Carolina at Chapel Hill.
Genotyping. Tail DNA was isolated by using a Wizard SV genomic DNA kit
(Promega). A PCR was set up in a volume of 20 l with 2 SYBR PCR mix
(Applied Biosystems, Foster City, CA), 1.7 ng of genomic DNA, and 125 nmol
of primers. PCR was performed according to the following protocol: 5 min at
94°C, followed by 40 cycles of 15 s at 94°C, 30 s at 55°C, and 1 min at 72°C for
CD19 primers (5-CCTCTCCCTGTCTCCTTCCT-3 and 5-TGGTCTGAGAC
ATTGACAATCA-3) and Cre primers (5-GCGGTCTGGCAGTAAAAACTA
TC-3 and 5-GTGAAACAGCATTGCTGTCACTT-3). PCRs were preheated
for 5 min at 94°C, followed by 40 cycles of 10 s at 94°C and 30 s at 62°C for LANA
primers (2454F [TGGCCCATCTCGCGAATA] and 2581R [GGACCGGTGG
TTGTTGGTAT]). The PCR products for CD19 and Cre were mixed together
and run on one lane on a 3% agarose gel for each mouse. A 100-bp molecular
weight marker (New England Biolabs, Ipswich, MA) was loaded on a separate
lane on each gel. PCR amplification for KSHV LANA and murine apoB was
conducted as described previously (21).
B-cell isolation and proliferation assay. B cells were purified from a mouse
spleen immunized with NP-KLH via elimination of non-B cells using an EasySep
mouse B-cell enrichment kit (Stemcell, Vancouver, Canada). The percentage of
CD19 enriched B cells was 96 to 97%, when assessed by fluorescence-activated
cell sorting. Purified B cells were cultured in RPMI 1640 medium supplemented
with 20% fetal bovine serum, 2 mM L-glutamine, penicillin (0.05 g/ml), and
streptomycin (5 U/ml) (Invitrogen, Inc., Carlsbad, CA) at 37°C under 5% CO2.
Purified B cells were stimulated with 50 g of lipopolysaccharide (LPS)/ml (from
Escherichia coli O111:B4; Invivogen) or left unstimulated in the aforementioned
culture medium containing interleukin-4 (IL-4; 10 U/ml; Peprotech, Rocky Hill,
NJ) and IL-5 (1 ng/ml; Peprotech). Proliferation of the B cells was measured with
CFSE (carboxyfluorescein diacetate succinimidyl ester; Invitrogen) labeling.
Briefly, B cells were labeled with 1 M CFSE, cultured for 4 days, and analyzed
by flow cytometry. Live cells were gated by using a Live/Dead fixable dead cell
stain kit (Invitrogen).
Flow cytometry. Single-cell suspensions of mouse spleen were isolated as
described previously (21). Flow cytometry analysis was performed by using CyAn
(Beckman-Coulter, Fullerton, CA). Further analysis was conducted with FlowJo
(version 7.2.5; Tree Star, Inc., Ashland, OR) and R version 2.8.0 (2008-10-20).
Antibodies. Alexa Fluor 488-conjugated anti-B220 (clone RA3-6B2), fluores-
cein isothiocyanate (FITC)-conjugated anti-mouse activation antigen GL7
(clone GL7, Ly77), anti-mouse IgD (clone 11-26c.2a), phycoerythrin (PE)-con-
jugated anti-mouse CD21/CD35 (clone 7G6), anti-mouse IgM (clone R6-60.2),
and PE/Cy5.5-conjugated anti-mouse CD45R (clone RA3-6B2) monoclonal an-
tibodies were purchased from BD Biosciences (Franklin Lakes, NJ). Alexa Fluor
555-conjugated streptavidin, allophycocyanin (APC)-conjugated anti-mouse
CD19 (clone 6D5), anti-mouse CD23 (clone B3B4), streptavidin, FITC-conju-
gated anti-mouse CD24 (clone CT-HAS), anti-mouse CD69 (clone H1.2F3),
and PE-conjugated anti-mouse CD86 (clone RMMP-2) were obtained from
Invitrogen (Camarillo, CA). Biotinylated metallophilic macrophages antibody
(MOMA1) was obtained from Abcam (Cambridge, MA). Biotinylated peanut
agglutinin (PNA) was purchased from Vector Laboratories (Burlingame, CA).
Anti-GL7 antibody was purchased from eBioscience (San Diego, CA).
Immunohistochemistry. Spleens were removed, fixed in 10% neutral buffered
formalin, embedded in paraffin, and processed by routine methods to obtain
5-m sections. Dewaxed sections were microwaved in 1 mM EDTA (pH 8.0) for
PNA staining for 15 min, cooled, treated with 3% H2O2, blocked with blocking
solution (10% horse serum, 5% bovine serum albumin, and 0.3% Triton X-100
in PBS), and incubated overnight with the appropriate primary antibody. Detec-
tion was performed with a VectaStain ABC kit, a Vector DAB peroxidase
substrate kit for PNA, and a Vector NovaRED peroxidase substrate kit for GL7
(Vector Laboratories, Inc.).
For MOMA1 detection, spleens were removed and mounted with tissue freez-
ing medium. Cryosections (6 m) were cut with a cryotome (Leica CM1850 UV),
air dried, fixed in cold acetone for 10 min, washed with PBS, dried, and stored in
an airtight box at 80°C. The slides were dried in air before use. Immunohis-
tochemical assays were done as described previously (21) with modifications.
Briefly, cryosections were fixed in cold acetone for 10 min at 4°C, air dried, and
rehydrated in PBS. Slides were incubated for 15 min with a blocking solution
consisting of 10% (vol/vol) fetal bovine serum in PBS. Sections were washed
three times in a washing buffer (PBS containing 0.05% Triton X-100) and stained
for 18 h at 4°C with the appropriate primary antibodies. Sections were washed
again and incubated for 2 h with secondary antibody. Finally, slides were washed
with a washing buffer three times and mounted in VectaShield mounting medium
(Vector Laboratories, Inc.).
Statistical analysis. We used the R statistical package (version 2.10.1) for all
of our calculations. We used a t test or nonparametric Wilcoxon signed rank test
for comparisons between two groups. Both yielded consistent results. We used n
 5 animals per group. For experiments involving two factors (transgene and
treatment), we used analysis of variance (ANOVA) to establish overall and
individual factor significance levels. This was possible since our experimental
design was balanced with regard to its statistical properties.
RESULTS
LANA augments the acute B-cell response to antigen. We
previously observed mature (CD19 IgD IgM) B-cell hy-
peractivation and hyperplasia in our B-cell-specific KSHV
LANA transgenic mice. We hypothesized that LANA lowers
the threshold of mature B cells to respond to antigens. To test
this hypothesis, we injected mice once with the NP-KLH model
antigen or saline (36, 51). Eight days later, which is before the
onset of affinity maturation (reviewed in reference 1), we in-
vestigated the primary B-cell response in the spleen. Impor-
tantly, this experiment did not use any adjuvant and thus mim-
icked natural, weak antigen exposure.
Activated B cells were defined as CD19 PNA CD71hi and
quantified by flow cytometry (Fig. 1A). PNA is a well-estab-
lished marker for activated B cells (51), and CD71 (transferrin
receptor) is an early lymphocyte activation marker (31). CD71
is also expressed on PEL cells (5). Mock-treated C57BL/6 mice
(n  10) had background levels of activated B cells (mean 
24.48%). NP-KLH immunized C57BL/6 mice (n  5) showed
the expected increase in activated B cells (mean  40.98%).
LANA transgenic mice in the absence of specific immunization
presented with the same frequency of activated B cells as
purposely immunized nontransgenic mice (n  10, mean 
41.19%). LANA transgenic mice also upregulated the CD68
activation marker on CD19 B cells in the absence of specific
immunization (data not shown). Upon immunization with NP-
KLH the number of activated GC B cells increased further in
the LANA transgenic mice (n  6, mean  46.40%). It in-
creased above the background frequency in LANA transgenic
mock-treated mice and above the frequency of nontransgenic,
immunized mice. Some of the NP-KLH immunized LANA
transgenic mice had the highest number of activated GC B
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cells of all animals in this experiment (maximum of 63%).
ANOVA showed a significant difference between all groups.
Based on multivariate analysis, both the LANA transgene (P 
0.00001) and NP-KLH immunization (P  0.002) contributed
independently and additively to the observed phenotypes. This
demonstrates that LANA augments the primary B-cell re-
sponse to background and experimental antigens.
We verified this result by using immunohistochemistry for
the late GC marker GL7 (Fig. 1B). GL7 is expressed in cen-
trocytes (23). It is a more stringent marker than PNA or CD71
since it identifies cells that completed the GC reaction. We did
not observe any GL7 foci in mock-treated C57BL/6 mice.
GL7 foci, i.e., GC, were induced by NP-KLH in C57BL/6
mice. LANA transgenic mice exhibited GL7 foci in the ab-
sence of specific antigen stimulation, a finding consistent with
a lower activation threshold to environmental antigen expo-
sure in LANA transgenic compared to wild-type mice. NP-
KLH-immunized LANA transgenic mice exhibited GL7 GC,
which is consistent with acute antigen exposure, although this
analysis did not detect a difference in the size or frequency of
GC in KLH-immunized compared to nonimmunized LANA
transgenic mice.
We interpret these data to mean that LANA lowers the
threshold of B-cell activation. In the absence of specific immu-
nization, any mature B-cell with a BCR of any affinity to any
environmental or chance antigen can become activated. In the
absence of LANA this signal is short-lived or never reaches the
threshold to induce a proliferative phenotype or GC reaction.
In the presence of LANA this threshold is lowered.
If LANA lowers the activation threshold of naive B cells,
leading to continual activation, then this may lead to B-cell
exhaustion. We therefore investigated the proliferative re-
sponse of purified CD19 positive B cells in culture (Fig. 2).
Since NP-KLH is a T-dependent antigen, we could not use NP
to stimulate purified B cells. Instead, we tested the hypothesis
that purified B cells from LANA or wild-type mice respond
equally well to the standard polyclonal stimulus LPS. LPS is
used as positive control in many B-cell proliferation studies.
We purified B cells by negative selection to avoid inadvertently
activating them. Purified B cells were stimulated with 50 g of
LPS (from Escherichia coli O111:B4)/ml as published else-
where (40), and proliferation was determined by CFSE assay
over 4 days.
B cells from LANA transgenic mice proliferated more in
response to LPS than B cells from nontransgenic littermates
(Fig. 2A and C). The difference was statistically significant to
P  0.005 using the Wilcoxon rank sum test (Fig. 2E). This
result corroborated our in vivo data that LANA augmented the
B-cell response. B cells from NP-KLH-immunized mice re-
sponded equally well to LPS in culture, whether derived from
LANA transgenic or wild-type mice (Fig. 2B and D). There
was no statistically significant difference in their responses. We
interpret these data to mean that even though LANA induces
hyper-responsiveness in B cells in vivo, this does not lead to
exhaustion.
LANA does not restore the B-cell defect in CD19 knockout
mice. A key proposition of our threshold modulation model is
that LANA-associated B-cell hyperactivation is a BCR-depen-
dent rather than a cell-autonomous phenotype. We therefore
sought to determine whether LANA could complement an
absolute defect in BCR signaling as seen in CD19-deficient
mice. CD19 is part of the BCR signaling complex (51). CD19
is not required for B cells to mature into IgM IgD cells, but
the lack of CD19 manifests itself by the absence of GC (19, 61).
CD19/ mice also lack MZ cells. CD19/ mice in the
C57BL/6 background were obtained from Jackson Labs
(Fig. 3A).
The double heterozygous F1 mice (LANA
/ CD19/)
exhibited the LANA-associated B-cell hyperplasia phenotype
similarly to LANA/ CD19/ homozygous animals, as de-
termined by the frequency of B220 IgD PNA cells (Fig.
3B, right side). We used B220 as a B-cell marker here to
capture any and all B cells in the CD19/ mice. The CD19/
LANA/ transgenic animals seemed to have slightly higher
numbers of activated IgD cells (Fig. 3B, left side). However,
within the group of CD19/ animals this difference was not
statistically significant. ANOVA incorporating all animals (n 
30) established that LANA conferred a proliferative pheno-
FIG. 1. LANA augments the B-cell response to immunization.
(A) Box plot of flow cytometry results. The frequency of triple-positive
(CD19 PNA CD71) among CD19 was determined and plotted.
The transgene status is shown on the bottom, and the treatment is
shown at the top of the graph. A dot indicates the median, the box
indicates the interquartile range (IQR), bars denote the range, and
open dots denote outliers (1.5  IQR). NP-KLH, 4-hydroxy-3-nitro-
phenylacetyl–keyhole limpet hemocyanin; LANA, LANA transgenic;
WT, wild type. (B) Immunohistochemistry against GL7 antigen
(brown) and hematoxylin (blue). Shown are representative images of
spleen (magnification, 40) for wild-type (WT), LANA transgenic
(LANA), wild-type NP-KLH-immunized (WT-KLH), and LANA
NP-KLH-immunized (LANA-KLH) animals.
VOL. 84, 2010 LANA AUGMENTS B-CELL RESPONSE TO ANTIGEN IN VIVO 10655
type (P  106), even in CD19/ hypomorphic animals, and
that the lack of CD19 conferred the expected loss of IgD
PNA cells (P  5  1015). LANA, however, was not able to
overcome this, the predominant phenotype.
As determined by hematoxylin and eosin (H&E) staining of
spleen sections, the LANA/ CD19/ animals shared the
phenotype of the CD19/ parent. Figure 3C and D show
spleen sections of a C57BL/6 (LANA/ CD19/) mouse
with clearly demarcated, isolated GC and MZ regions between
the red and white pulp. Figure 3E and F show spleen sections
of a LANA transgenic mouse ((LANA/ CD19/). As we
previously observed in 100% of LANA transgenic mice, the
spleen is disorganized, with enlarged, irregular GC and ex-
panded MZ. Often, the GC run into each other, and the red
pulp zone is diminished. Figure 3G and H show spleen sections
of a LANA/ CD19/, which are indistinguishable from
transgene-negative CD19/ mice (19; data not shown). Note
the absence of GC (light zone), a sharply shrunk MZ around
them, but the presence of clearly demarcated, isolated foci,
unlike the hyperplasia seen in the presence of CD19. We
conclude that LANA was not able to compensate for the lack
of CD19 in GC development and that LANA-induced B-cell
hyperactivation requires BCR signaling.
To visualize the GC, we used PNA as a marker (Fig. 3I to
K). Wild-type mice show a few, very small PNA-positive
staining foci. LANA transgenic mice show many, extended,
irregular PNA-positive staining foci, as well as individual
PNA-positive cells outside of organized follicles. The
LANA/ CD19/ exhibited no PNA positivity, either as
foci or as individual cells. This represents the CD19/
phenotype. The presence of the LANA transgene did not
rescue the GC defect in CD19/ mouse.
To independently verify these results, we analyzed a second
cohort of age-matched 15- to 21-week-old LANA/ CD19/
mice (n  9) with LANA/ CD19/ (n  6) mice by using
multicolor flow cytometry analysis (Table 1). CD19/ mice
develop normal follicular B-cell (B220 CD21 CD23
CD24lo) compartment (41), and LANA//CD19/ mice at
15 to 21 weeks old showed a similar percentage of follicular B
cells as LANA//CD19/ mice (Table 1). Comparing
LANA//CD19/ mice with LANA//CD19/ (F2) re-
vealed no GC formation associated with LANA expression in
the absence of CD19 signaling (Table 1).
LANA restores the MZ defect in CD19 knockout mice par-
tially. CD19/ mice show severe reduction in MZ B cells
(B220 CD21hi CD23 CD24) (19, 35, 42, 51). We found
increased MZ cells in LANA//CD19/ mice (3.46% 
1.08, n  9) compared to LANA//CD19/ mice (2.05% 
0.45, n  6). Representative results are shown in Fig. 4A and
B. The percentage of MZ B cells in the age-matched
LANA//CD19/ littermates controls was 8.71%  2.16.
Although MZ comprise only a minor fraction of B cells in
normal mice, we were able to detect a statistically significant
difference (P  0.003 using ANOVA) using sets of three-
color (B220 CD21hi CD23, Fig. 4C) and four-color flow
cytometry markers (B220 CD21hi CD23 CD24; data not
shown). This demonstrates that LANA can rescue the CD19
deficiency-associated defect in the MZ B-cell development
partially.
We confirmed this result by using immune fluorescence mi-
croscopy assay (IFA). Spleens from age-matched mice were
stained using MOMA-1, a marker for marginal zone macro-
phages, and B220, a pan-B-cell marker. We did not use CD19
as a B-cell marker, since of course CD19 would be absent in
the CD19/ background. In wild-type mice, MOMA-1 marks
the middle of the marginal zone (Fig. 4D, wt). B cells are
present in between MOMA-1-positive macrophages, within
the MOMA-1 ring demarking the GC center and, importantly,
FIG. 2. LANA augments the proliferative capacity of B cells in
culture. (A to D) Examples of flow cytometric analysis of purified
cultured B cells labeled with CFSE after 4-day stimulation with LPS
(gray density) or nonstimulation control (open diagram). Stimulation
is measured by the fraction of cells that lose fluorescent intensity. The
horizontal line (and number) indicates the gate that was used for
quantification. The CFSE fluorescence intensity is shown on the hor-
izontal axis, and the number of cells as a percentage of the maximum
is shown on the vertical axis. Results with B cells from LANA trans-
genic mice are shown in panels C and D, and results from wild-type
littermate control animals are shown in panels A and B. Animals in
panels B and D were in vivo stimulated by NP-KLH immunization
prior to harvest. (E) Box-and-whisker plot of the results from multiple
animals. A dot indicates the median, a box indicates the interquartile
range (IQR), bars indicate the range, and open dots denote outliers
(1.5  IQR). The three asterisks indicate a significant difference
between groups of six LANA and six wild-type mice at P  0.005 as
determined by using the Wilcoxon rank sum test.
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also outside the MOMA-1 ring. In CD19/ mice, MOMA-1
staining was reduced and no B220-positive cells were notice-
able adjacent to the MOMA-1-positive cells (Fig. 4D, CD19/).
Furthermore, the B220-positive clusters were fewer and
smaller compared to wild-type mice. This represents the typical
phenotype of CD19/ mice (19, 48, 51). The presence of the
LANA transgene rescued the marginal zone B-cell deficiency
of the CD19/. Corroborating our quantitative, multiparam-
eter flow cytometric analysis, the immune fluorescence image
now revealed many more MOMA-1-positive cells in typical
MZ morphology (Fig. 4D, CD19/  LANA). Also, B220 B
cells (green) can now be observed adjacent to MOMA-1 MZ
FIG. 3. LANA does not complement the B-cell deficiency in CD19 knockout mice. (A) Shown is a representative picture of an ethidium
bromide-stained 1% agarose–TAE gel of PCR products using mouse tail DNA. One hundred-base-pair molecular weight markers are shown on
the left (MW); inferred genotypes are shown at the top. WT, wild type; NTC, nontemplate control. (B) Box plot of flow cytometry results (n 
30, animals are not incorporated in Table 1). The frequency of triple-positive (B220 IgD PNA) was determined and plotted. The LANA
transgene status is shown at the bottom, and the CD19 status is shown at the top of the graph. Dot indicates the median, a box indicates the
interquartile range (IQR), bars indicate the range, and open dots denote outliers (1.5  IQR). del, deletion for CD19 (CD19/); wt (top),
CD19/; LANA, LANA transgenic; wt, wild-type (LANA/). The morphology of the spleen in wild-type (C and D), LANA transgenic (E and
F), and CD19//LANA/ (G and H) mice is shown. Representative H&E-stained images are presented. The upper row is at 100 magnification,
the lower row is at 40 magnification. MZ, marginal zone, GC, germinal center. The asterisk in panel G denotes the absence of GC in
CD19//LANA/ mice. Immunohistochemistry for PNA (brown) counterstained with hematoxylin (blue) was performed. Representative
sections for wild-type (I), LANA transgenic (J), and CD19//LANA/ (K) mice are presented.
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macrophages (red) and also outside the ring of MZ macro-
phages (white arrows in Fig. 4D, CD19/  LANA). Fur-
thermore, B220 fluorescence was brighter in CD19/ 
LANA compared to wild-type or CD19/ mice. This pheno-
type is due to the LANA transgene, since CD19/ hypomor-
phic, LANA transgenic mice also have significantly more and
brighter B220-positive cells compared to LANA transgene-
negative littermates (data not shown).
DISCUSSION
The molecular mechanisms by which KSHV latent genes,
such as LANA, lead to B-cell hyperplasia, such as MCD, or
frank DLBCL, such as PEL, are poorly understood. A number
of mechanisms have been proposed for LANA-dependent cell
transformation. These include interactions with the cellular
antiapoptotic proteins p53, and pRb, as well as signaling path-
ways that are involved in proliferation (reviewed in reference
14). Biochemical studies show that LANA protein binds to
GSK3	 (22), as well as a growing number of cellular transcrip-
tion factors, and that it activates the human telomerase pro-
moter (2, 3, 12, 30, 33, 43, 53). Microarray analyses found that
LANA specifically induced only a very limited number of
mRNAs (2, 47). This implies that KSHV LANA activates mul-
tiple cellular survival pathways in B cells. This phenotype was
recapitulated in the LANA transgenic mice.
We examined B-cell populations of LANA transgenic mice
with CD19 deficiency background. LANA rescued the MZ
B-cell defect of CD19-deficient mice but not the GC defect of
CD19-deficient mice. MZ B cells constitute the first wave of
the B-cell response to antigen (reviewed in reference 46). They
respond to low-affinity antigen encounter, and their response is
short-lived by design. Since they do not necessarily require the
multitude of finely tuned B-cell-T-cell interactions that take
place within the GC, it is conceivable that the MZ defect in
CD19 knockout mice was rescued by inducing an activated
state through this viral transcription factor.
Other signaling molecules have been implicated in CD19
signaling and MZ formation. PTEN deletion can rescue the
CD19/ defect completely (6). BAFF:BAFF-R is also re-
quired for MZ formation, and canonical NF-
B activity
brought about by constitutive active I
B kinase 2 can rescue
MZ development in BAFF-R/ mice (50). However, NF-
B
does not complement the CD19/ defect, i.e., substitute for
the tonic BCR signaling that is required for B-cell maturation.
Notch-RBP-j is also involved in MZ formation (57), and
LANA has been shown to interact with this pathway (11, 33).
Finally, and perhaps most consistently, signaling through
PI3K-Akt is essential for B-cell survival and BCR signaling in
mice (13, 25, 55).
We immunized LANA transgenic mice and found that
LANA augmented the primary, BCR-dependent, GC response
to (i) acute antigen above control, and (ii) above the level of
chronic activation, such as results from inadvertent microbial
translocation. This would ensure that cells expressing LANA,
i.e., virally infected B cells, are preferentially amplified upon
antigen encounter. BCR signal strength is crucial to B-cell
proliferation, differentiation, and survival (19, 51, 58). Thus,
lowering the BCR signaling threshold provides a novel mech-
anism for viral persistence in B cells.
Other B-cell-tropic herpesviruses provide examples of mech-
anistically different scenarios, which nevertheless yield the
same result. EBV latent genes also confer a proliferative ad-
vantage upon B cells in transgenic mice, and LMP2A enhances
B-cell responses in vivo (4, 52, 56, 60). This reflects the evolu-
tionary conservation of B-cell signaling and its importance in
gammaherpesvirus latency. Conceptually, the progrowth phe-
notype of the EBV LMP-1 and LMP-2A transgenic mice is
easier to comprehend since these two molecules are located in
the membrane and impinge on BCR signaling receptor prox-
imately: they bind receptor-associated kinases via SH- or
TRAF-binding domains. Our experiments suggest that
LANA engages the same signaling pathways, only further
downstream, since LANA is localized in the nucleus.
The B-cell-tropic murine herpesvirus 68 (MHV68) encodes
a presumptive superantigen (59) and is known to require B-cell
proliferation and, of course, LANA, for the establishment of
latency (32, 38, 39, 44). The T-cell-tropic herpesvirus saimiri
also encodes a superantigen, which is required for oncogenesis
in primates (17, 29). MHV68 is known to activate host mac-
rophages (7), which results in protection from certain bacterial
pathogens, and there exists an established association between
EBV-positive Burkitt lymphoma and malaria, which many be-
lieve centers around chronic exposure to parasite antigens
TABLE 1. Summary of cell surface marker analysis of wild-type, CD19-deficient, and LANA-transgenic, CD19-deficient mice
Class Marker
B-cell subpopulations in LANA-transgenic and LANA-transgenic  CD19-deficient
animalsa
PbLANA/ CD19/ LANA/ CD19/
% SD n % SD n
Early GC B220 PNA IgD 0.68 0.65 11 1.53 1.31 7 NS
Late GC B220 PNA IgD 0.28 0.27 11 1.12 1.73 7 NS
Early GC B220 PNA GL7 0.97 0.73 11 1.89 1.62 7 NS
Late GC B220 PNA GL7 0.96 0.82 11 1.84 1.44 7 NS
Activated PNA CD69 4.44 1.6 11 5.53 1.30 7 NS
Activated B220 CD86 6.18 2.10 11 8.56 4.85 7 NS
FOc B220 CD21 CD23 85.7 3.82 6 82.1 4.42 9 NS
MZ B220 CD21hi CD23 2.05 0.45 6 3.46 1.08 9 0.01
a n, Number of animals.
b NS, not significant.
c FO, follicular.
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(49). Thus, by manipulating B-cell signaling, herpesviruses sup-
port the expansion of latent cells.
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